Tonix Pharmaceuticals Holding Corp. 8K

Tonix Pharmaceuticals reported Q1 2026 results and pipeline progress, including early TONMYA launch metrics, strengthened payer access, multiple mid-stage clinical plans, additional ATM equity proceeds, and cash runway into early Q2 2027 amid continued operating losses.

Tonix Pharmaceuticals Holding Corp. filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended March 31, 2026 and providing operational updates, highlighting net product revenue of approximately $6.9 million (including $3.7 million from recently launched fibromyalgia drug TONMYA), a cash balance of about $185.5 million, expanded commercial uptake and payer coverage for TONMYA, continued commercialization of migraine products Zembrace SymTouch and Tosymra, progression of multiple pipeline programs across CNS, infectious disease, immunology, and rare diseases (including Phase 2 plans for TNX-102 SL in MDD, an adaptive Phase 2 Lyme disease prevention study for TNX-4800 targeted for 2027, and upcoming Phase 2 work on TNX-1500 and TNX-2900), and disclosure that the company raised $22.6 million in additional capital via its at-the-market equity facility and believes its cash resources will fund operations into early second quarter 2027 despite a quarterly net loss of approximately $40.2 million.

Filing Facts

CIK

1430306

Ticker

-

Form

8K

Source Type

sec

Accession

0001999371-26-010487

Alert Tier

6